Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial

被引：0

作者：

Gladman, Dafna D. ^{[1
]}

Rigby, William ^{[2
]}

Azevedo, Valderilio F. ^{[3
,4
,5
]}

Behrens, Frank ^{[6
]}

Blanco, Ricardo ^{[7
]}

Kaszuba, Andrzej ^{[8
]}

Kudlacz, Elizabeth ^{[9
]}

Wang, Cunshan ^{[9
]}

Menon, Sujatha ^{[9
]}

Hendrikx, Thijs ^{[10
]}

Kanik, Keith S. ^{[9
]}

机构：

[1] Univ Toronto, Toronto, ON, Canada

[2] Dartmouth Hitchcock Med Ctr, Rheumatol, Lebanon, NH 03766 USA

[3] Univ Fed Parana, Curitiba, Parana, Brazil

[4] Edumed Hlth Res Ctr, Curitiba, Parana, Brazil

[5] Biotech, Curitiba, Parana, Brazil

[6] Goethe Univ Frankfurt, Frankfurt, Germany

[7] Hosp Univ Marques de Valdecilla, IDIVAL, Rheumatol, Santander, Spain

[8] Specialstyczne Gabinety Lerkarskie DERMED, Lodz, Poland

[9] Pfizer Inc, Groton, CT 06340 USA

[10] Pfizer Inc, Collegeville, PA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

10L

引用

页数：5

共 50 条

[1] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial
Gladman, Dafna
Rigby, William
Azevedo, Valderilio
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB114 - AB114
[2] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: OPAL BEYOND, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Gladman, D. D.
Rigby, W. F. C.
Azevedo, V. F.
Behrens, F.
Blanco, R.
Kaszuba, A.
Kudlacz, E.
Wang, C.
Menon, S.
Hendrikx, T.
Kanik, K. S.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 135 - 136
[3] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo-Controlled, Phase 3 Trial
Mease, Philip J.
Hall, Stephen
FitzGerald, Oliver
van der Heijde, Desiree
Merola, Joseph F.
Avila-Zapata, Francisco
Cieslak, Dorata
Graham, Daniela
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[4] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs: OPAL Broaden, a randomized, placebo-controlled, phase 3 trial
Mease, Philip
Hall, Stephen
FitzGerald, Oliver
van der Heijde, Desiree
Merola, Joseph
Avila-Zapata, Francisco
Graham, Daniela
Wang, Cunshan
Kanik, Keith
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB114 - AB114
[5] Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Merola, Joseph
Landewe, Robert
McInnes, Iain B.
Mease, Philip J.
Ritchlin, Christopher
Tanaka, Yoshiya
Asahina, Akihiko
Behrens, Frank
Gladman, Dafna
Gossec, Laure
Warren, Richard
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Coarse, Jason
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3169 - 3171
[6] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Mease, P. J.
Hall, S.
FitzGerald, O.
van der Heijde, D.
Merola, J. F.
Avila-Zapata, F.
Cieslak, D.
Graham, D.
Wang, C.
Menon, S.
Hendrikx, T.
Kanik, K. S.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 141 - 142
[7] Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
Leng, Xiaomei
Lin, Wei
Liu, Shixue
Kanik, Keith
Wang, Cunshan
Wan, Weiguo
Jiang, Zhenyu
Liu, Yi
Liu, Shengyun
Zhang, Zhuoli
Zhang, Zhiyi
Xu, Jian
Tan, Wenfeng
Hu, Jiankang
Li, Jingyang
Liu, Ju
Gunay, Levent M.
Dina, Oluwaseyi
Kinch, Cassandra
Zeng, Xiaofeng
RMD OPEN, 2023, 9 (01):
[8] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
Strand, Vibeke
de Vlam, Kurt
Covarrubias-Cobos, Jose A.
Mease, Philip J.
Gladman, Dafna D.
Chen, Linda
Kudlacz, Elizabeth
Wu, Joseph
Cappelleri, Joseph C.
Hendrikx, Thijs
Hsu, Ming-Ann
RMD OPEN, 2019, 5 (01):
[9] Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Merola, Joseph F.
Landewe, Robert
McInnes, Iain B.
Mease, Philip J.
Ritchlin, Christopher T.
Tanaka, Yoshiya
Asahina, Akihiko
Behrens, Frank
Gladman, Dafna D.
Gossec, Laure
Gottlieb, Alice B.
Thaci, Diamant
Warren, Richard B.
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Shende, Vishvesh
Coarse, Jason
Coates, Laura C.
LANCET, 2023, 401 (10370): : 38 - 48
[10] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Mease, P. J.
Deodhar, A.
Van der Heijde, D.
Behrens, F.
Kivitz, A.
Kim, J.
Singhal, S.
Nowak, M.
Banerjee, S.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 314 - 315

← 1 2 3 4 5 →